Quintiles has been named a preferred provider to 14 global health Product Development Partnerships (PDPs), a consortium that leverages their combined pipelines in an effort the get the most cost effective use of their R&D spend. PDPs are not-for-profit entities seeking to discover, develop and deliver new affordable medicines for some of the most neglected diseases in the world.

The 14 PDPs anticipate funding 128 Phase I-IV trials over the next two years. Quintiles will partner with the consortium to provide access to its global clinical development infrastructure, particularly in the area of infectious diseases such as HIV, malaria and tuberculosis.

“Quintiles is extremely pleased to have been chosen by the consortium members,” said Dr. Kelly McKee, Quintiles vice president and managing director, Public Health and Government Services. “The work they’re doing has the potential to reshape global health within a generation. The public health issues on which they are focused have the potential to save millions of lives. We are very excited to be named a preferred provider to the consortium and look forward to helping advance this critical mission.”